Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition
Abstract Natriuretic peptides exert multiple effects by binding to natriuretic peptide receptors (NPRs). Osteocrin (OSTN) binds with high affinity to NPR-C, a clearance receptor for natriuretic peptides, and inhibits degradation of natriuretic peptides and consequently enhances guanylyl cyclase-A (G...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ee6ea24a24204f86924bd4ac7c5ffbb8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ee6ea24a24204f86924bd4ac7c5ffbb8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ee6ea24a24204f86924bd4ac7c5ffbb82021-11-14T12:17:33ZOsteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition10.1038/s41598-021-01095-82045-2322https://doaj.org/article/ee6ea24a24204f86924bd4ac7c5ffbb82021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01095-8https://doaj.org/toc/2045-2322Abstract Natriuretic peptides exert multiple effects by binding to natriuretic peptide receptors (NPRs). Osteocrin (OSTN) binds with high affinity to NPR-C, a clearance receptor for natriuretic peptides, and inhibits degradation of natriuretic peptides and consequently enhances guanylyl cyclase-A (GC-A/NPR1) signaling. However, the roles of OSTN in the kidney have not been well clarified. Adriamycin (ADR) nephropathy in wild-type mice showed albuminuria, glomerular basement membrane changes, increased podocyte injuries, infiltration of macrophages, and p38 mitogen-activated protein kinase (MAPK) activation. All these phenotypes were improved in OSTN- transgenic (Tg) mice and NPR3 knockout (KO) mice, with no further improvement in OSTN-Tg/NPR3 KO double mutant mice, indicating that OSTN works through NPR3. On the contrary, OSTN KO mice increased urinary albumin levels, and pharmacological blockade of p38 MAPK in OSTN KO mice ameliorated ADR nephropathy. In vitro, combination treatment with ANP and OSTN, or FR167653, p38 MAPK inhibitor, reduced Ccl2 and Des mRNA expression in murine podocytes (MPC5). OSTN increased intracellular cyclic guanosine monophosphate (cGMP) in MPC5 through GC-A. We have elucidated that circulating OSTN improves ADR nephropathy by enhancing GC-A signaling and consequently suppressing p38 MAPK activation. These results suggest that OSTN could be a promising therapeutic agent for podocyte injury.Takaya HandaKeita P. MoriAkira IshiiShoko OhnoYugo KanaiHaruko Watanabe-TakanoAkihiro YasodaTakashige KuwabaraNobuyuki TakahashiNaoki MochizukiMasashi MukoyamaMotoko YanagitaHideki YokoiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Takaya Handa Keita P. Mori Akira Ishii Shoko Ohno Yugo Kanai Haruko Watanabe-Takano Akihiro Yasoda Takashige Kuwabara Nobuyuki Takahashi Naoki Mochizuki Masashi Mukoyama Motoko Yanagita Hideki Yokoi Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition |
| description |
Abstract Natriuretic peptides exert multiple effects by binding to natriuretic peptide receptors (NPRs). Osteocrin (OSTN) binds with high affinity to NPR-C, a clearance receptor for natriuretic peptides, and inhibits degradation of natriuretic peptides and consequently enhances guanylyl cyclase-A (GC-A/NPR1) signaling. However, the roles of OSTN in the kidney have not been well clarified. Adriamycin (ADR) nephropathy in wild-type mice showed albuminuria, glomerular basement membrane changes, increased podocyte injuries, infiltration of macrophages, and p38 mitogen-activated protein kinase (MAPK) activation. All these phenotypes were improved in OSTN- transgenic (Tg) mice and NPR3 knockout (KO) mice, with no further improvement in OSTN-Tg/NPR3 KO double mutant mice, indicating that OSTN works through NPR3. On the contrary, OSTN KO mice increased urinary albumin levels, and pharmacological blockade of p38 MAPK in OSTN KO mice ameliorated ADR nephropathy. In vitro, combination treatment with ANP and OSTN, or FR167653, p38 MAPK inhibitor, reduced Ccl2 and Des mRNA expression in murine podocytes (MPC5). OSTN increased intracellular cyclic guanosine monophosphate (cGMP) in MPC5 through GC-A. We have elucidated that circulating OSTN improves ADR nephropathy by enhancing GC-A signaling and consequently suppressing p38 MAPK activation. These results suggest that OSTN could be a promising therapeutic agent for podocyte injury. |
| format |
article |
| author |
Takaya Handa Keita P. Mori Akira Ishii Shoko Ohno Yugo Kanai Haruko Watanabe-Takano Akihiro Yasoda Takashige Kuwabara Nobuyuki Takahashi Naoki Mochizuki Masashi Mukoyama Motoko Yanagita Hideki Yokoi |
| author_facet |
Takaya Handa Keita P. Mori Akira Ishii Shoko Ohno Yugo Kanai Haruko Watanabe-Takano Akihiro Yasoda Takashige Kuwabara Nobuyuki Takahashi Naoki Mochizuki Masashi Mukoyama Motoko Yanagita Hideki Yokoi |
| author_sort |
Takaya Handa |
| title |
Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition |
| title_short |
Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition |
| title_full |
Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition |
| title_fullStr |
Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition |
| title_full_unstemmed |
Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition |
| title_sort |
osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/ee6ea24a24204f86924bd4ac7c5ffbb8 |
| work_keys_str_mv |
AT takayahanda osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT keitapmori osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT akiraishii osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT shokoohno osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT yugokanai osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT harukowatanabetakano osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT akihiroyasoda osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT takashigekuwabara osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT nobuyukitakahashi osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT naokimochizuki osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT masashimukoyama osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT motokoyanagita osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition AT hidekiyokoi osteocrinamelioratesadriamycinnephropathyviap38mitogenactivatedproteinkinaseinhibition |
| _version_ |
1718429323162025984 |